Gastric stasis in migraineurs: Etiology, characteristics, and clinical and therapeutic implications

Cephalalgia

Volumn 33, Issue 6, 2013, Pages 408-415

  Aurora, Sheena K ^a   Papapetropoulos, Spyridon ^b,c   Kori, Shashidhar H ^d   Kedar, Archana ^e   Abell, Thomas L ^e  

^a SWEDISH MEDICAL CENTER   (United States)

^b ALLERGAN INC   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d MAP Pharmaceuticals   (United States)

^e UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

Autonomic diseases; gastric stasis; gastrointestinal; migraine

Indexed keywords

ACETYLSALICYLIC ACID; METOCLOPRAMIDE; PARACETAMOL; RIZATRIPTAN; TOLFENAMIC ACID; TRIMEBUTINE; TRIPTAN DERIVATIVE; ZOLMITRIPTAN;

AKATHISIA; AREA UNDER THE CURVE; AUTONOMIC NEUROPATHY; CLINICAL FEATURE; CONTROLLED STUDY; CYCLIC VOMITING SYNDROME; DISEASE ASSOCIATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; GASTRIC STASIS; HUMAN; HYPERPROLACTINEMIA; MAXIMUM PLASMA CONCENTRATION; MIGRAINE; NEUROPATHOLOGY; OUTCOME ASSESSMENT; PARKINSONISM; PATHOPHYSIOLOGY; REVIEW; RISK BENEFIT ANALYSIS; STOMACH DISEASE; STOMACH EMPTYING; STOMACH FUNCTION DISORDER; STOMACH SCINTISCANNING; TARDIVE DYSKINESIA; VOMITING; AUTONOMIC NERVOUS SYSTEM; STOMACH PARESIS;

AUTONOMIC NERVOUS SYSTEM; GASTROPARESIS; HUMANS; MIGRAINE DISORDERS;

EID: 84884164780     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1177/0333102412473371     Document Type: Review

References (61)

1. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24(Suppl 1): 9-160.
2. Stewart WF, Lipton RB, Celentano DD, et al. Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA 1992; 267: 64-69.
3. Buse DC, Rupnow MF, Lipton RB,. Assessing and managing all aspects of migraine: Migraine attacks, migraine-related functional impairment, common comorbidities, and quality of life. Mayo Clin Proc 2009; 84: 422-435.
4. Volans GN,. Migraine and drug absorption. Clin Pharmacokinet 1978; 3: 313-318.
5. Parrish CR, Gastrointestinal issues in persons with diabetes. In: Powers MA, (ed.) Handbook of diabetes medical nutrition therapy, Gaithersburg, MD: Aspen Publishers, 1996, pp. 618-637.
6. Masaoka T, Tack J,. Gastroparesis: Current concepts and management. Gut Liver 2009; 3: 166-173.
7. Waseem S, Moshiree B, Draganov PV,. Gastroparesis: Current diagnostic challenges and management considerations. World J Gastroenterol 2009; 15: 25-37.
8. Soykan I, Sivri B, Sarosiek I, et al. Demography, clinical characteristics, psychological and abuse profiles, treatment, and long-term follow-up of patients with gastroparesis. Dig Dis Sci 1998; 43: 2398-2404.
9. Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: Data from the American Migraine Study II. Headache 2001; 41: 646-657.
10. Schurks M, Buring JE, Kurth T,. Migraine, migraine features, and cardiovascular disease. Headache 2010; 50: 1031-1040.
11. Spierings EL,. Symptomatology and pathogenesis of migraine. J Pediatr Gastroenterol Nutr 1995; 21 (Suppl 1): S37-S41.
12. Porreca F, Ossipov MH,. Nausea and vomiting side effects with opioid analgesics during treatment of chronic pain: Mechanisms, implications, and management options. Pain Med 2009; 10: 654-662.
13. Reddymasu SC, Bonino J, McCallum RW,. Gastroparesis secondary to a demyelinating disease: A case series. BMC Gastroenterol 2007; 7: 3-3.
14. Peroutka SJ,. Migraine: A chronic sympathetic nervous system disorder. Headache 2004; 44: 53-64.
15. Peroutka SJ,. Re: A sympathetic view of "2003 Wolff Award: Possible parasympathetic contributions to peripheral and central sensitization during migraine". Headache 2004; 44: 731-732.
16. Chelimsky TC, Chelimsky GG,. Autonomic abnormalities in cyclic vomiting syndrome. J Pediatr Gastroenterol Nutr 2007; 44: 326-330.
17. Rapoport AM, Freitag F, Pearlman SH,. Innovative delivery systems for migraine: The clinical utility of a transdermal patch for the acute treatment of migraine. CNS Drugs 2010; 24: 929-940.
18. Shechter A, Stewart WF, Silberstein SD, et al. Migraine and autonomic nervous system function: A population-based, case-control study. Neurology 2002; 58: 422-427.
19. Dalla Volta G, Anzola GP, DiMonda V,. The disappearance of the "cold patch" in recovered migraine patients: Thermographic findings. Headache 1991; 31: 305-309.
20. Welch KM, Nagesh V, Aurora SK, et al. Periaqueductal gray matter dysfunction in migraine: Cause or the burden of illness? Headache 2001; 41: 629-637.
21. Kruit MC, Launer LJ, Ferrari MD, et al. Infarcts in the posterior circulation territory in migraine. The population-based MRI CAMERA study. Brain 2005; 128: 2068-2077.
22. Dodick DW, Gargus JJ,. Why migraines strike. Sci Am 2008; 299: 56-63.
23. Bandler R, Carrive P,. Integrated defence reaction elicited by excitatory amino acid microinjection in the midbrain periaqueductal grey region of the unrestrained cat. Brain Res 1988; 439: 95-106.
24. Smith GS, Savery D, Marden C, et al. Distribution of messenger RNAs encoding enkephalin, substance P, somatostatin, galanin, vasoactive intestinal polypeptide, neuropeptide Y, and calcitonin gene-related peptide in the midbrain periaqueductal grey in the rat. J Comp Neuro 1994; 350: 23-40.
25. Moskowitz MA, The trigeminovascular system. In: Olesen J, Tfelt-Hansen P, Welch KMA, (eds). The Headaches, New York: Raven Press, Ltd, 1993, pp. 97-104.
26. Mainero C, Boshyan J, Hadjikhani N,. Altered functional magnetic resonance imaging resting-state connectivity in periaqueductal gray networks in migraine. Ann Neurol 2011; 70: 838-845.
27. Cao Y, Aurora SK, Nagesh V, et al. Functional MRI-BOLD of brainstem structures during visually triggered migraine. Neurology 2002; 59: 72-78.
28. Kruit MC, van Buchem MA, Launer LJ, et al. Migraine is associated with an increased risk of deep white matter lesions, subclinical posterior circulation infarcts and brain iron accumulation: The population-based MRI CAMERA study. Cephalalgia 2010; 30: 129-136.
29. Welch KM, Cao Y, Aurora S, et al. MRI of the occipital cortex, red nucleus, and substantia nigra during visual aura of migraine. Neurology 1998; 51: 1465-1469.
30. Tepper SJ, Rezai A, Narouze S, et al. Acute treatment of intractable migraine with sphenopalatine ganglion electrical stimulation. Headache 2009; 49: 983-989.
31. Cecchini AP, Mea E, Tullo V, et al. Vagus nerve stimulation in drug-resistant daily chronic migraine with depression: Preliminary data. Neurol Sci 2009; 30 (Suppl 1): S101-S104.
32. McCorry LK,. Physiology of the autonomic nervous system. Am J Pharm Educ 2007; 71: 78-78.
33. Kellow JE, Delvaux M, Azpiroz F, et al. Principles of applied neurogastroenterology: Physiology/motility-sensation. Gut 1999; 45 (Suppl 2): II17-II24.
34. Ramkumar D, Schulze KS,. Gastroduodenal motility. Curr Opin Gastroenterol 2003; 19: 540-545.
35. Abell TL, Camilleri M, Donohoe K, et al. Consensus recommendations for gastric emptying scintigraphy: A joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. Am J Gastroenterol 2008; 103: 753-763.
36. McClelland GR, Sutton JA,. Epigastric impedance: A non-invasive method for the assessment of gastric emptying and motility. Gut 1985; 26: 607-614.
37. Nyholm D, Lennernäs H,. Irregular gastrointestinal drug absorption in Parkinson's disease. Expert Opin Drug Metab Toxicol 2008; 4: 193-203.
38. Tokola RA, Neuvonen PJ,. Effects of migraine attack and metoclopramide on the absorption of tolfenamic acid. Br J Clin Pharmacol 1984; 17: 67-75.
39. Tokola RA, Neuvonen PJ,. Effect of migraine attacks on paracetamol absorption. Br J Clin Pharmacol 1984; 18: 867-871.
40. Volans GN,. Absorption of effervescent aspirin during migraine. Br Med J 1974; 4: 265-268.
41. Aurora S, Kori S, Barrodale P, et al. Gastric stasis occurs in spontaneous, visually induced, and interictal migraine. Headache 2007; 47: 1443-1446.
42. Aurora SK, Kori SH, Barrodale P, et al. Gastric stasis in migraine: More than just a paroxysmal abnormality during a migraine attack. Headache 2006; 46: 57-63.
43. Cheng LK, O'Grady G, Du P, et al. Gastrointestinal system. Wiley Interdiscip Rev Syst Biol Med 2010; 2: 65-79.
44. Ferrari A, Tiraferri I, Neri L, et al. Why pharmacokinetic differences among oral triptans have little clinical importance: A comment. J Headache Pain 2011; 12: 5-12.
45. Thomsen LL, Dixon R, Lassen LH, et al. 311C90 (zolmitriptan), a novel centrally and peripheral acting oral 5-hydroxytryptamine-1D agonist: A comparison of its absorption during a migraine attack and in a migraine-free period. Cephalalgia 1996; 16: 270-275.
46. Krymchantowski AV, Filho PF, Bigal ME,. Rizatriptan vs. rizatriptan plus trimebutine for the acute treatment of migraine: A double-blind, randomized, cross-over, placebo-controlled study. Cephalalgia 2006; 26: 871-874.
47. Lee A, Kuo B,. Metoclopramide in the treatment of diabetic gastroparesis. Expert Rev Endocrinol Metab 2010; 5: 653-662.
48. Marmura MJ,. Use of dopamine antagonists in treatment of migraine. Curr Treat Options Neurol 2012; 14: 27-35.
49. Phillips WJ, Tollefson B, Johnson A, et al. Relief of acute pain in chronic idiopathic gastroparesis with intravenous phentolamine. Ann Pharmacother 2006; 40: 2032-2036.
50. Fuseau E, Petricoul O, Moore KH, et al. Clinical pharmacokinetics of intranasal sumatriptan. Clin Pharmacokinet 2002; 41: 801-811.
51. Fox AW,. Subcutaneous sumatriptan pharmacokinetics: Delimiting the monoamine oxidase inhibitor effect. Headache 2010; 50: 249-255.
52. Dahlöf CG,. Non-oral formulations of triptans and their use in acute migraine. Curr Pain Headache Rep 2005; 9: 206-212.
53. Boyle R, Behan PO, Sutton JA,. A correlation between severity of migraine and delayed gastric emptying measured by an epigastric impedance method. Br J Clin Pharmacol 1990; 30: 405-409.
54. Pareek N, Fleisher DR, Abell T,. Cyclic vomiting syndrome: What a gastroenterologist needs to know. Am J Gastroenterol 2007; 102: 2832-2840.
55. Fleisher DR, Gornowicz B, Adams K, et al. Cyclic vomiting syndrome in 41 adults: The illness, the patients, and problems of management. BMC Med 2005; 3: 20-20.
56. Hejazi RA, Lavenbarg TH, McCallum RW,. Spectrum of gastric emptying patterns in adult patients with cyclic vomiting syndrome. Neurogastroenterol Motil 2010; 22: 1298-1302, e338.
57. Ladabaum U, Hasler WL,. Novel approaches to the treatment of nausea and vomiting. Dig Di 1999; 17: 125-132.
58. Soffer E, Abell T, Lin Z, et al. Review article: Gastric electrical stimulation for gastroparesis-physiological foundations, technical aspects and clinical implications. Aliment Pharmacol Ther 2009; 30: 681-694.
59. Grover I, Shivangi K, Kedar A, et al. Gastric stimulation is an option for patients with refractory cyclical vomiting syndrome: One year follow up. Presented at: Digestive Disease Week (DDW) 2011, Chicago, IL, 7-11 May 2011, poster Tu1388.
60. Christensen CJ, Johnson WD, Abell TL,. Patients with cyclic vomiting pattern and diabetic gastropathy have more migraines, abnormal electrogastrograms, and gastric emptying. Scand J Gastroenterol 2008; 43: 1076-1081.
61. Peroutka SJ,. 2008: The year in review. Headache 2009; 49: 796-802.